Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Cosentyx Drug Market Size, Value And Growth Trajectory Through 2030
The cosentyx drug market has experienced robust expansion over recent years. Forecasts indicate it will expand from $5.68 million in 2025 to reach $6.21 million by 2026, demonstrating a compound annual growth rate (CAGR) of 9.2%. Factors contributing to this historical growth include the approval of IL 17 inhibitors, the significant prevalence of psoriasis and arthritis, the inadequate response to TNF inhibitors, increased adoption by specialist dermatology practices, and the establishment of biologic treatment guidelines.
The market size for the Cosentyx drug is expected to show significant expansion over the next few years. It is forecast to achieve a valuation of $8.74 million by 2030, growing at a compound annual growth rate (CAGR) of 8.9%. This projected growth is driven by increased diagnosis of autoimmune diseases, a broadening of treatment indications, greater patient awareness, improved access to biologic therapies, and supporting long-term efficacy data. Important trends anticipated during this forecast period include the rising adoption of IL-17 inhibitor therapies, the expanded application across various autoimmune conditions, a shift towards targeted biologic treatments, more frequent use of long-term maintenance therapy, and an increasing demand for self-injectable biologics.
Get A Free Sample Report With In-Depth Market Insights:
Cosentyx Drug Market Development Factors: What’s Supporting Demand?
The increasing occurrence of autoimmune diseases is anticipated to boost the growth of the Cosentyx market in the future. Autoimmune diseases are disorders where the immune system mistakenly attacks healthy cells and tissues within the body. The rise in these diseases is linked to genetic predispositions, environmental factors such as infections and pollutants, and lifestyle adjustments, including increased stress and dietary shifts. Cosentyx (secukinumab) aids patients with autoimmune diseases by specifically targeting and inhibiting interleukin-17A, a key cytokine in inflammation, thereby alleviating symptoms, improving life quality, and effectively managing conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. For instance, in August 2024, data from Public Health Scotland, a national organization in Scotland, reported that the Scottish Multiple Sclerosis Register (SMSR) recorded 455 newly diagnosed MS patients in 2023. Therefore, the growing prevalence of autoimmune diseases is a significant driver for the Cosentyx market.
Cosentyx Drug Market Segment Analysis Spotlighting Growth Areas
The cosentyx drug market covered in this report is segmented –
1) By Indication: Hidradenitis suppurativa, Psoriatic arthritis, Ankylosing spondylitis, Plaque Psoriasis
2) By Route Of Administration: Subcutaneous injection, Intravenous infusion
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
Cosentyx Drug Market Transformation Trends: What Innovations Are Driving Change?
Leading companies in the cosentyx drug market are focusing on developing advanced therapies, such as biological treatment options, to address unmet medical needs, enhance treatment efficacy, and provide targeted therapies for managing chronic autoimmune conditions. This strategy aims to strengthen their market position and cater to a growing patient population. Biologic treatments are sophisticated therapies derived from living organisms or their cells that specifically target components of the immune system, such as interleukin-17A, to modulate inflammatory responses and effectively treat autoimmune conditions like psoriasis, psoriatic arthritis, and ankylosing spondylitis. For instance, in October 2023, Novartis AG, a Switzerland-based pharmaceutical company, received FDA approval for Cosentyx (secukinumab) as the first new biologic treatment option for moderate to severe hidradenitis suppurativa (HS) in nearly a decade. This approval marks a significant advancement in the treatment landscape for HS, a chronic and often debilitating skin condition characterized by painful lumps that can lead to scarring and psychological distress.
Cosentyx Drug Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the cosentyx drug market are Novartis AG
View The Full Cosentyx Drug Market Report:
Cosentyx Drug Market Regional Breakdown: Where Is Demand Concentrated?
North America was the largest region in the cosentyx drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cosentyx drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
